Form 4: Catalyst Pharmaceuticals Executive Brian Elsbernd Reports Stock Transactions

Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities.

Summary

• On March 3, 2025, Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, executed transactions involving the company's stock.
• Elsbernd acquired 9,270 shares of common stock at $2.24 per share and disposed of 9,720 shares at a weighted average price of $23.23.
• He also acquired 53,255 shares at $2.24 per share and disposed of 53,255 shares at a weighted average price of $22.93.
• These transactions resulted in Elsbernd holding 188,564 shares of common stock following the reported transactions.
• Additionally, Elsbernd exercised options to purchase common stock, acquiring 9,270 and 53,255 options at $2.24, resulting in holdings of 1,062,339 and 1,009,084 options respectively.
• The options vested in three annual tranches beginning on December 19, 2019, and expire on December 19, 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions. The provided explanation indicates the sales were for personal reasons, mitigating potential negative interpretations.

Management Comments

• Shares were sold for personal reasons and not as a result of a disagreement with the Company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the buying and selling activities of company executives. It's a standard practice in publicly traded companies and helps maintain market integrity.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• The reported transactions are typical for executives who receive stock options as part of their compensation packages.
• Similar filings can be observed for executives at comparable pharmaceutical companies like Biogen, Amgen, and Vertex Pharmaceuticals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, providing insight into executive sentiment, but are unlikely to significantly alter the company's fundamentals.
• Employees may be indirectly affected by the perceived confidence of leadership, but the stated reason for the sale (personal reasons) mitigates potential concerns.

Key Dates